{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:58:00Z","timestamp":1775746680686,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dry eye disease (DED) is a condition that compromises the ocular surface and affects millions of people around the world. In recent years, a scheme has been proposed for the treatment of DED, with the use of artificial tear being the mainstay of treatment. In this scheme, the use of secretagogues is suggested as part of the treatment for patients with moderate to severe affectation. With this systematic review, we aim to evaluate the effectiveness and safety of secretagogues for DED.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Electronic databases will be searched; we will include randomized controlled trials that compare secretagogues and artificial tears. Study inclusion will not be restricted on the basis of language or publication status. We will use Google Translate to assess studies written in languages other than English and Spanish. Identification, evaluation, data extraction, and assessment of risk of bias will be conducted by two authors of the review, a third review author will resolve any disagreement. The outcomes will be the ocular surface disease index score, tear film break-up time, Schirmer test score, VRQoL Score, and tear film osmolarity. We will use the Cochrane Collaboration Risk of Bias 2 (RoB 2) tool for assessing the risk of bias of the included studies.<\/jats:p>\n                <jats:p>Based on the heterogeneity of the included studies, we will combine the findings in a meta-analysis using a fixed effect model if heterogeneity\u2009\u2264\u200950% or a random effect model if heterogeneity\u2009&gt;\u200950%. If we deem meta-analysis as inappropriate, we will document the reasons and report findings from the individual studies narratively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Based on the evidence obtained, we will evaluate the effect of pilocarpine, cevimeline, and diquafosol and compare it to artificial tears on multiple outcome measures.<\/jats:p>\n                <jats:p>This systematic review aims to determine the efficacy and safety of the secretagogues pilocarpine, cevimeline, and diquafosol to help clinicians in the decision-making process.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>PROSPERO <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42020218407\">CRD42020218407<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13643-022-01979-4","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T12:02:48Z","timestamp":1653739368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and efficacy of pilocarpine, cevimeline, and diquafosol compared to artificial tears for the treatment of dry eye: protocol for a\u00a0systematic review"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2926-219X","authenticated-orcid":false,"given":"Jos\u00e9 Gerardo","family":"Serrano-Robles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8138-678X","authenticated-orcid":false,"given":"Ana Karen","family":"P\u00e9rez V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Navas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique O.","family":"Graue-Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Ramirez-Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3887-0629","authenticated-orcid":false,"given":"Nicol\u00e1s","family":"Kahuam-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,28]]},"reference":[{"issue":"4","key":"1979_CR1","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1167\/iovs.10-6997e","volume":"52","author":"DA Schaumberg","year":"2011","unstructured":"Schaumberg DA, Nichols JJ, Papas EB, Tong L, Uchino M, Nichols KK. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for MGD. Invest Ophthalmol Vis Sci. 2011;52(4):1994\u20132005.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"1979_CR2","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1167\/iovs.10-6997","volume":"52","author":"KK Nichols","year":"2011","unstructured":"Nichols KK. The international workshop on meibomian gland dysfunction: introduction. Invest Ophthalmol Vis Sci. 2011;52(4):1917\u201321.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"1979_CR3","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1167\/iovs.10-6997b","volume":"52","author":"J Daniel Nelson","year":"2011","unstructured":"Daniel Nelson J, Shimazaki J, Benitez-del-Castillo JM, Craig J, McCulley JP, Den S, et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci. 2011;52(4):1930\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"23","key":"1979_CR4","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1056\/NEJMra1407936","volume":"378","author":"JA Clayton","year":"2018","unstructured":"Clayton JA. Dry eye. N Engl J Med. 2018;378(23):2212\u201323.","journal-title":"N Engl J Med"},{"key":"1979_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ajo.2019.01.026","volume":"202","author":"R Dana","year":"2019","unstructured":"Dana R, Bradley JL, Guerin A, Pivneva I, Stillman I\u00d6, Evans AM, et al. Estimated prevalence and incidence of dry eye disease based on coding analysis of a large, all-age United States health care system. Am J Ophthalmol. 2019;202:47\u201354.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"1979_CR6","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1167\/iovs.10-6997c","volume":"52","author":"E Knop","year":"2011","unstructured":"Knop E, Knop N, Millar T, Obata H, Sullivan DA. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci. 2011;52(4):1938\u201378.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"1979_CR7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1001\/archophthalmol.2009.356","volume":"128","author":"KL Miller","year":"2010","unstructured":"Miller KL, Walt JG, Mink DR, Satram-Hoang S, Wilson SE, Perry HD, et al. Minimal clinically important difference for the ocular surface disease index. Arch Ophthalmol. 2010;128(1):94\u2013101.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"1979_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40135-013-0009-1","volume":"1","author":"M Uchino","year":"2013","unstructured":"Uchino M, Schaumberg DA. Dry eye disease: impact on quality of life and vision. Current Ophthalmology Reports. 2013;1(2):51\u20137.","journal-title":"Current Ophthalmology Reports"},{"issue":"4","key":"1979_CR9","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1167\/iovs.10-6997d","volume":"52","author":"KB Green-Church","year":"2011","unstructured":"Green-Church KB, Butovich I, Willcox M, Borchman D, Paulsen F, Barabino S, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on tear film lipids and lipid-protein interactions in health and disease. Invest Ophthalmol Vis Sci. 2011;52(4):1979\u201393.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"1979_CR10","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1167\/iovs.10-6997f","volume":"52","author":"A Tomlinson","year":"2011","unstructured":"Tomlinson A, Bron AJ, Korb DR, Amano S, Paugh JR, Ian Pearce E, et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci. 2011;52(4):2006\u201349.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"1979_CR11","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jtos.2017.08.003","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, et al. TFOS DEWS II report executive summary. Ocular Surface. 2017;15(4):802\u201312.","journal-title":"Ocular Surface"},{"issue":"3","key":"1979_CR12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","volume":"15","author":"JS Wolffsohn","year":"2017","unstructured":"Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, et al. TFOS DEWS II diagnostic methodology report. Ocular Surface. 2017;15(3):539\u201374. Available from: https:\/\/doi.org\/10.1016\/j.jtos.2017.05.001.","journal-title":"Ocular Surface."},{"key":"1979_CR13","doi-asserted-by":"crossref","unstructured":"Rauz S, Koay S-Y, Foot B, Kaye SB, Figueiredo F, Burdon MA, et al. The Royal College of Ophthalmologists guidelines on serum eye drops for the treatment of severe ocular surface disease: full report. Eye. 2017;1\u201316.","DOI":"10.1038\/eye.2017.209"},{"issue":"3","key":"1979_CR14","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","volume":"15","author":"L Jones","year":"2017","unstructured":"Jones L, Downie LE, Korb D, Benitez-del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II management and therapy report. Ocular Surface. 2017;15(3):575\u2013628. Available from: https:\/\/doi.org\/10.1016\/j.jtos.2017.05.006.","journal-title":"Ocular Surface."},{"issue":"1","key":"1979_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12886-018-1008-7","volume":"19","author":"CH Park","year":"2019","unstructured":"Park CH, Lee HK, Kim MK, Kim EC, Kim JY, Kim TI, et al. Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial. BMC Ophthalmology. 2019;19(1):1\u201310.","journal-title":"BMC Ophthalmology."},{"issue":"1","key":"1979_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-13121-9","volume":"7","author":"J Shimazaki","year":"2017","unstructured":"Shimazaki J, Seika D, Saga M, Fukagawa K, Sakata M, Iwasaki M, et al. A prospective, randomized trial of two mucin secretogogues for the treatment of dry eye syndrome in office workers. Sci Rep. 2017;7(1):1\u201310.","journal-title":"Sci Rep"},{"issue":"1","key":"1979_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ajo.2004.02.010","volume":"138","author":"M Ono","year":"2004","unstructured":"Ono M, Takamura E, Shinozaki K, Tsumura T, Hamano T, Yagi Y, et al. Therapeutic effect of cevimeline on dry eye in patients with Sj\u00f6gren\u2019s syndrome: a randomized, double-blind clinical study. Am J Ophthalmol. 2004;138(1):6\u201317.","journal-title":"Am J Ophthalmol"},{"key":"1979_CR18","unstructured":"Bohm KJ, Djalilian AR, Pflugfelder SC, Starr CE. Part v The ocular adnexa section 4 disorders of tear production and the lacrimal system dry eye lacrimal functional unit: anatomy and physiology. In: Cornea. 2017. p. 377\u201395."},{"issue":"10","key":"1979_CR19","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1136\/bjophthalmol-2011-301448","volume":"96","author":"E Takamura","year":"2012","unstructured":"Takamura E, Tsubota K, Watanabe H, Ohashi Y. A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol. 2012;96(10):1310\u20135.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1979_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-45475-7","volume":"9","author":"S Fukuoka","year":"2019","unstructured":"Fukuoka S, Arita R. Tear film lipid layer increase after diquafosol instillation in dry eye patients with meibomian gland dysfunction: a randomized clinical study. Sci Rep. 2019;9(1):1\u201311.","journal-title":"Sci Rep"},{"issue":"7","key":"1979_CR21","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1136\/bjophthalmol-2014-306084","volume":"99","author":"L Gong","year":"2015","unstructured":"Gong L, Sun X, Ma Z, Wang Q, Xu X, Chen X, et al. A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore. Br J Ophthalmol. 2015;99(7):903\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"14 Special Issu","key":"1979_CR22","doi-asserted-by":"publisher","first-page":"DES116","DOI":"10.1167\/iovs.18-24130","volume":"59","author":"H Watanabe","year":"2018","unstructured":"Watanabe H. Medical treatment for dry eye in Japan. Investigative Ophthalmology and Visual Science. 2018;59(14 Special Issue):DES116-20.","journal-title":"Investigative Ophthalmology and Visual Science."},{"issue":"3","key":"1979_CR23","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s12016-014-8438-7","volume":"49","author":"V Valim","year":"2015","unstructured":"Valim V, Trevisani VFM, de Sousa JM, Vilela VS, Belfort R. Current approach to dry eye disease. Clin Rev Allergy Immunol. 2015;49(3):288\u201397.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"1979_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1542-0124(12)70043-5","volume":"4","author":"P Buchholz","year":"2006","unstructured":"Buchholz P, Steeds CS, Stern LS, Wiederkehr DP, Doyle JJ, Katz LM, et al. Utility assessment to measure the impact of dry eye disease. Ocular Surface. 2006;4(3):155\u201361.","journal-title":"Ocular Surface"},{"key":"1979_CR25","doi-asserted-by":"crossref","unstructured":"Julian P.T. Higgins, James Thomas, Jacqueline Chandler, Miranda Cumpston, Tianjing Li MJP and VAW. Cochrane Handbook for Systematic Reviews of Interventions. Second Edi. Cochrane Handbook for Systematic Reviews of Interventions. Oxford,: Wilet Blackwell; 2019.","DOI":"10.1002\/9781119536604"},{"issue":"75","key":"1979_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","volume":"1","author":"J McGowan","year":"2016","unstructured":"McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol. 2016;1(75):40\u20136.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"1979_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","volume":"10","author":"ML Rethlefsen","year":"2021","unstructured":"Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, et al. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews. Syst Rev. 2021;10(1):39.","journal-title":"Syst Rev"},{"key":"1979_CR28","unstructured":"Veritas Health Innovation. Covidence. [Internet]. Melbourne, Australia: Veritas Health Innovation, 2020; [Cited 2020 Sep 4]. Available from: https:\/\/www.covidence.org\/"},{"key":"1979_CR29","doi-asserted-by":"crossref","unstructured":"Navas A, Eo G, Ibarra A. LASIK in adults with myopia or myopic astigmatism ( Review ). 2020;","DOI":"10.1002\/14651858.CD012946.pub2"},{"key":"1979_CR30","first-page":"1","volume-title":"Review Manager 5 (RevMan 5)","author":"TC Collaboration","year":"2014","unstructured":"Collaboration TC. Review Manager 5 (RevMan 5). Copenhagen: Nordic Cochrane Centre; 2014. p. 1\u201343."},{"key":"1979_CR31","unstructured":"Plot Digitizer [Internet]. [Cited 2022 Apr 1]. Available from: http:\/\/plotdigitizer.sourceforge.net\/"},{"key":"1979_CR32","first-page":"1","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. The BMJ. 2019;366:1\u20138.","journal-title":"The BMJ"},{"key":"1979_CR33","unstructured":"Julian Higgins JT. Chapter 10: Analysing data and undertaking meta-analyses | Cochrane Training [Internet]. 2019 [cited 2021 May 27]. p. 10.2.1. Available from: https:\/\/training.cochrane.org\/handbook\/current\/chapter-10#section-10-10-2"},{"key":"1979_CR34","unstructured":"GRADE handbook [Internet]. [cited 2022 Apr 1]. Available from: https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-022-01979-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-022-01979-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-022-01979-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T12:09:15Z","timestamp":1653739755000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-022-01979-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,28]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1979"],"URL":"https:\/\/doi.org\/10.1186\/s13643-022-01979-4","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,28]]},"assertion":[{"value":"19 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}